Erratum: Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani(Université Paris-Sud), Laurence Zitvogel(Institut Gustave Roussy), Luana Calabrò(University of Siena), Christine Mateus(Centre National de la Recherche Scientifique), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Mélanie Desbois(Immunocore (United Kingdom)), Sylvie Rusakiewicz(Inserm), Phillip Wong(Memorial Sloan Kettering Cancer Center), Michele Maio(University of Siena), Dirk Schadendorff(Essen University Hospital), Nicolas Jacquelot(University of Calgary), Nathalie Chaput(Institut Gustave Roussy), Andrzej Maćkiewicz(Poznan University of Medical Sciences), Alan J. Korman(Bristol-Myers Squibb (Germany)), David Klatzmann(Inserm), Salem Chouaı̈b(Inserm), James P. Allison(The University of Texas MD Anderson Cancer Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Marie Vétizou(Innate Pharma (France)), Jedd D. Wolchok(Cornell University), Mark J. Smyth(Peter MacCallum Cancer Centre), Guido Kroemer(Institut Universitaire de France), Antoni Ribas(University of California, Los Angeles), Nadège Vimond(Inserm), David Enot(Institut Gustave Roussy), Jianda Yuan, Caroline Robert(Institut Gustave Roussy), Jacek Mackiewicz(Poznan University of Medical Sciences), Keith S. Bahjat(Providence Portland Medical Center), Dirk Jaeger(Memorial Sloan Kettering Cancer Center), Michele W.L. Teng(The University of Queensland)
Cited by 133
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k